Affiliation:
1. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang
Avenue #1277, Wuhan, 430022, China
2. Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
Abstract
Purpose:
To investigate the safety and efficacy of lobaplatin-TACE in the treatment of primary hepatocellular carcinoma.
Method:
The data of 536 patients who underwent TACE in the interventional department from January 2016 to January 2020 were collected. Patients were divided into two groups according to the chemotherapeutic drugs used in TACE.: epirubicin-TACE group(N = 260), lobaplatin-TACE group(N = 276). Primary study endpoint: (1) The tumor response after TACE; (2)The survival rates ; Secondary study endpoints:(1)Changes of liver function and blood routine before and after TACE;(2)Occurrence of post-embolization syndrome and infection after TACE.
Results:
The ORR was 35.0% in epirubicin-TACE group and 51.1% in lobaplatin-TACE group(P=0.001). The DCR was 73.1% in epirubicin-TACE group and 82.2% in lobaplatin-TACE group(P=0.011). The 6-month, 9-month, 12-month, and 15-month survival rates were higher in the lobaplatin-TACE group than in the epirubicin-TACE group(P=0.029,P=0.001,P=0.005,P=0.002). mOS: Epirubicin-TACE group,14.8 months; Lobaplatin-TACE group,18.6 months (P =0.007). mPFS: Epirubicin-TACE group,9.5 months; Lobaplatin-TACE group,12.8 months (P =0.000). There was no statistical difference in ALT, AST, total bilirubin and Leucocyte after TACE between the two groups (P=0.343,P=0.368,P=0.288,P=0.359). The platelet decrease after TACE was more significant in the lobaplatin-TACE group than in the epirubicin-TACE group (P=0.046). There was no statistical difference in the incidence rate of abdominal pain, fever and infection after TACE between the two groups (P=0.502,P=0.602,P=0.726).The incidence of vomiting after TACE in the lobaplatin-TACE group was higher than that in the epirubicin-TACE group (P=0.003).
Conclusion:
Lobaplatin-TACE has higher tumor response rate and survival rate.Lobaplatin-TACE is a safe and effective treatment strategy,it is worthy of clinical application.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference42 articles.
1. Clark T.; Maximin S.; Meier J.; Pokharel S.; Bhargava P.; Hepatocellular carcinoma: Review of epidemiology, screening, imaging diag-nosis, response assessment, and treatment. Curr Probl Diagn Radiol 2015,44(6),479-486
2. Budny A.; Kozłowski P.; Kamińska M.; Jankiewicz M.; Kolak A.; Budny W.; Niemunis-Sawicka J.; Szczypior G.; Kurniawka B.; Burdan F.; Epidemiology and risk factors of hepatocellular carcinoma. Pol Merkur Lekarski 2017,43(255),133-139
3. Hartke J.; Johnson M.; Ghabril M.; The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol 2017,34(2),153-159
4. Friedman M.A.; Volberding P.A.; Cassidy M.J.; Resser K.J.; Wasserman T.H.; Phillips T.L.; Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: A northern California oncology group study. Cancer Treat Rep 1979,63(11-12),1885-1888
5. Reuter S.R.; The current status of angiography in the evaluation of cancer patients. Cancer 1976,37(1)(Suppl.),532-541
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献